Inspire Medical Systems (INSP) EBITDA Margin (2017 - 2026)

Inspire Medical Systems has disclosed EBITDA Margin across 10 years of filings, most recently posting 0.55% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 0.55%, down 188.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.47% (up 754.0% YoY), and the FY2025 annual result was 15.94%, up 931.0% from the prior year.
• EBITDA Margin came in at 0.55% for Q1 2026 at Inspire Medical Systems, down from 50.51% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 50.51% in Q4 2025 to a low of 24.27% in Q1 2022.
• The 5-year median for EBITDA Margin is 0.55% (2026), against an average of 0.37%.
• Peak annual rise in EBITDA Margin reached 3630 bps in 2025, while the deepest fall reached 645 bps in 2025.
• Inspire Medical Systems' EBITDA Margin stood at 2.49% in 2022, then soared by 224 bps to 8.06% in 2023, then surged by 76 bps to 14.21% in 2024, then soared by 256 bps to 50.51% in 2025, then tumbled by 101 bps to 0.55% in 2026.
• The last three EBITDA Margin figures came in at 0.55% (Q1 2026), 50.51% (Q4 2025), and 4.53% (Q3 2025), per Business Quant data.